[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338043-105":59,"doc-detail-338043-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","drug-tolerant-persister-cell-plasticity-in-cancer-a-revolutionary-strategy-for-more-effective-anticancer-therapies","Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies","","Non-genetic mechanisms drive anticancer drug resistance, and the drug tolerant persister (DTP) cell phenotype is highlighted as a major non-genetic contributor. DTP cells adopt a quiescent or slow-cycle reversible state and inertly specialize to stimuli, enduring drug exposure via multiple underlying mechanisms and resuming growth after drug withdrawal. This review summarizes DTP formation characteristics, drug-tolerant pathways, candidate anti-DTP agents across drug models, and the need and feasibility of anti-DTP therapy to support future clinical translation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/drug-tolerant-persister-cell-plasticity-in-cancer-a-revolutionary-strategy-for-more-effective-anticancer-therapies/338043/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/drug-tolerant-persister-cell-plasticity-in-cancer-a-revolutionary-strategy-for-more-effective-anticancer-therapies/338043.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What defines DTP (drug tolerant persister) cells in cancer therapy resistance?","Question",{"text":112,"@type":113},"DTP cells are a cancer cell subgroup that enters a quiescent or slow-cell-cycle reversible state and persist in the drug environment. They tolerate anticancer drug exposure and recover growth after drug withdrawal, contributing to resistance and recurrence.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is targeting DTP cells considered a promising anticancer strategy?",{"text":117,"@type":113},"The review states that targeting DTP cells may offer new treatment opportunities because DTP cells play a predominant non-genetic role in resistance. However, current understanding of DTP mechanisms is still limited and requires further investigation.",{"name":119,"@type":110,"acceptedAnswer":120},"Has anti-DTP therapy been confirmed in clinical studies for humans?",{"text":121,"@type":113},"No clinical studies have yet confirmed the existence of DTP cells or the effectiveness of anti-DTP treatments in humans. The review emphasizes the lack of quantifiable understanding and unclear clinical direction as obstacles.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338043,1790887326,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nREVIEW ARTICLE  \nOPEN  \nDrug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies  \nJun He1,2, Zejing Qiu 1,2, Jingjing Fan1,2, Xiaohong Xie3 ✉, Qinsong Sheng4 ✉ and Xinbing Sui 1,2 ✉  \n\n|  | Non-genetic mechanisms have recently emerged as important drivers of anticancer drug resistance. Among these, the drug tolerant persister (DTP) cell phenotype is attracting more and more attention and giving a predominant non-genetic role in cancer therapy resistance. The DTP phenotype is characterized by a quiescent or slow-cell-cycle reversible state of the cancer cell subpopulation and inert specialization to stimuli, which tolerates anticancer drug exposure to some extent through the interaction of multiple underlying mechanisms and recovering growth and proliferation after drug withdrawal, ultimately leading to treatment resistance and cancer recurrence. Therefore, targeting DTP cells is anticipated to provide new treatment opportunities for cancer patients, although our current knowledge of these DTP cells in treatment resistance remains limited. In this review, we provide a comprehensive overview of the formation characteristics and underlying drug tolerant mechanisms of DTP cells, investigate the potential drugs for DTP (including preclinical drugs, novel use for old drugs, and natural products) based on different medicine models, and discuss the necessity and feasibility of anti-DTP therapy, related application forms, and future issues that will need tobe addressed to advance this emerging ﬁeld towards clinical applications. Nonetheless, understanding the novel functions of DTP |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| cells may enable us to develop new more effective anticancer therapy and improve clinical outcomes for cancer patients. |  |  |\n|  | Signal Transduction and Targeted Therapy (2024)9:209 ; [https://doi.org/10.1038/s41392-024-01891-4](https://doi.org/10.1038/s41392-024-01891-4) |  |\n|  |  |  |\n\nINTRODUCTION  \nResistance to anticancer drug therapy, especially ﬁrst-generation targeted therapy products, is a critical bottleneck in comprehensive anticancer treatment. For example, patients with lung cancer treated with Geﬁtinib, a ﬁrst-generation epidermal growth factor receptor (EGFR) inhibitor, typically develop resistance after 9 to 15 months of progression-free survival.1 Genetic mechanisms, such as mutations in the T790M gene,2,3 have been partially attributed to the development of drug resistance. However, evidence is increasingly pointing towards non-genetic mechanisms as playing a critical role in resistance development, with the presence of DTP cells being a key factor.4  \nDTP cells refer to a subgroup of cancer cells with distinct biological characteristics5 and internal mechanisms,6 allowing them to resist initial anticancer treatment. Unlike speciﬁc or characteristic cancer cells,7 DTP cells persist in the anticancer drug environment, exhibiting signiﬁcant variances from typical cancer cells in aspects such as cell-cycle, micro-environment regulation, and metabolism. These differences confer upon them the ability to endure and subsequently contribute to cancer recurrence and metastasis. Currently, research on the mechanism of DTP formation and drug resistance has primarily been conducted through cellular tests,8–12 animal tests,13–16, and mathematical models.13 Some studies have likewise mentioned the potential of anti-DTP treatments.8, 17, 18 However, no clinical studies have yet conﬁrmed the existence of DTP cells or the effectiveness of antiDTP treatments following anticancer therapy in humans. The lack  \nof quantiﬁable understanding of DTP and the unclear direction of its potential clinical treat","cbCaig9UIPdbqtOh","https://ap.wps.com/l/cbCaig9UIPdbqtOh","pdf",6000820,24,"English","# Introduction\n# Proposed DTP: Evolution of Research Developmentson DTP Cells\n## Chronicle of DTP cells","[{\"question\":\"What defines DTP (drug tolerant persister) cells in cancer therapy resistance?\",\"answer\":\"DTP cells are a cancer cell subgroup that enters a quiescent or slow-cell-cycle reversible state and persist in the drug environment. They tolerate anticancer drug exposure and recover growth after drug withdrawal, contributing to resistance and recurrence.\"},{\"question\":\"Why is targeting DTP cells considered a promising anticancer strategy?\",\"answer\":\"The review states that targeting DTP cells may offer new treatment opportunities because DTP cells play a predominant non-genetic role in resistance. However, current understanding of DTP mechanisms is still limited and requires further investigation.\"},{\"question\":\"Has anti-DTP therapy been confirmed in clinical studies for humans?\",\"answer\":\"No clinical studies have yet confirmed the existence of DTP cells or the effectiveness of anti-DTP treatments in humans. The review emphasizes the lack of quantifiable understanding and unclear clinical direction as obstacles.\"}]","Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies | PDF",1790021696,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f229ccf88e69c9cb84e4cc06ce6018e9.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/faecec9fab7759e4282dba3b7bf7df84.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6890b482889b0e9032b2f2582c05fb5.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52558b0547af5a8732cefc1d1c8d79ae.webp",980,1301]